Journal of Antimicrobial Chemotherapy, Vol 39, 15-21, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
DH Bouanchaud
Quinupristin/dalfopristin is a new water-soluble streptogramin
antimicrobial agent comprising quinupristin and dalfopristin in a ratio of
30:70. The in-vitro spectrum of activity includes most multi- resistant
Gram-positive aerobes, important Gram-negative aerobes, Gram- positive
anaerobes and intracellular bacteria that are causal agents of respiratory,
blood and cutaneous infections. Of particular note,
quinupristin/dalfopristin is active against multidrug-resistant isolates of
Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecium,
and against penicillin-resistant and/or erythromycin-resistant
Streptococcus pneumoniae. The combination is also active against
staphylococci showing both constitutive and inducible erythromycin
resistance. Bactericidal activity and a prolonged post-antibiotic effect
have also been noted for quinupristin/dalfopristin against Gram-positive
cocci. Gram-negative bacteria susceptible to quinupristin/dalfopristin
include Moraxella catarrhalis, Legionella spp. and Mycoplasma spp. Overall,
the spectrum of antibacterial activity indicates a potential role for this
combination in the treatment of difficult-to-treat Gram-positive
infections, including those caused by multidrug-resistant organisms. Since
this activity extends to Gram-negative respiratory bacteria,
quinupristin/dalfopristin may also find a role in the treatment of
atypical, as well as typical, pneumonia.
ORIGINAL ARTICLES
In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin
Rhone-Poulenc Rorer, Centre de Recherche de Vitry-Alfortville, Vitry- sur Seine, France.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. P. Allen, R. Cha, and M. J. Rybak In Vitro Activities of Quinupristin-Dalfopristin and Cefepime, Alone and in Combination with Various Antimicrobials, against Multidrug-Resistant Staphylococci and Enterococci in an In Vitro Pharmacodynamic Model Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2606 - 2612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E N Herbert, I A Pearce, J McGalliard, D Wong, and C Groenewald Vitreous penetration of levofloxacin in the uninflamed phakic human eye Br J Ophthalmol, April 1, 2002; 86(4): 387 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 {blacktriangledown}Quinupristin + dalfopristin for infections DTB, February 1, 2002; 40(2): 15 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Werner, C. Cuny, F.-J. Schmitz, and W. Witte Methicillin-Resistant, Quinupristin-Dalfopristin-Resistant Staphylococcus aureus with Reduced Sensitivity to Glycopeptides J. Clin. Microbiol., October 1, 2001; 39(10): 3586 - 3590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Zaoutis, L. S. Moore, K. Furness, and J. D. Klein In Vitro Activities of Linezolid, Meropenem, and Quinupristin-Dalfopristin against Group C and G Streptococci, Including Vancomycin-Tolerant Isolates Antimicrob. Agents Chemother., July 1, 2001; 45(7): 1952 - 1954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Rachid, K. Ohlsen, W. Witte, J. Hacker, and W. Ziebuhr Effect of Subinhibitory Antibiotic Concentrations on Polysaccharide Intercellular Adhesin Expression in Biofilm-Forming Staphylococcus epidermidis Antimicrob. Agents Chemother., December 1, 2000; 44(12): 3357 - 3363. [Abstract] [Full Text]
|
|
|
|
|
|
C. von Eiff, R. R. Reinert, M. Kresken, J. Brauers, and D. Hafner Nationwide German Multicenter Study on Prevalence of Antibiotic Resistance in Staphylococcal Bloodstream Isolates and Comparative In Vitro Activities of Quinupristin-Dalfopristin J. Clin. Microbiol., August 1, 2000; 38(8): 2819 - 2823. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Gander and R. Finch The effects of exposure at constant (1 h) or exponentially decreasing concentrations of quinupristin/dalfopristin on biofilms of Gram-positive bacteria J. Antimicrob. Chemother., July 1, 2000; 46(1): 61 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Harwell and R. B. Brown The Drug-Resistant Pneumococcus: Clinical Relevance, Therapy, and Prevention Chest, February 1, 2000; 117(2): 530 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Michelet, S. L. Leib, D. Bentue-Ferrer, and M. G. Täuber Comparative Efficacies of Antibiotics in a Rat Model of Meningoencephalitis Due to Listeria monocytogenes Antimicrob. Agents Chemother., July 1, 1999; 43(7): 1651 - 1656. [Abstract] [Full Text]
|
|
|
|
|
|
J. Andrews, J. Ashby, G. Jevons, N. Lines, and R. Wise Antimicrobial resistance in Gram-positive pathogens isolated in the UK between October 1996 and January 1997 J. Antimicrob. Chemother., May 1, 1999; 43(5): 689 - 698. [Abstract] [Full Text] [PDF]
|
|